Envision
lifelong
protection
against
cancer

Marengo Therapeutics is pioneering a new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer.

Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay.

An entirely different perspective on tackling cancer, using a novel mode of T cell activation

Marengo scientists have discovered a new approach: priming specific T cells to fight tumors by directly targeting Vβ TCR variants. Our first-in-class antibodies deploy this new approach.

Learn more

About Us

Our Mission

Activating the right immune response to promote lifelong protection against cancer.

Our Vision

To create a world in which everyone’s immune system can defeat cancer.

Leadership Team

Board of Directors

Our Science

An important biological discovery expands horizons for cancer treatment

The immuno-oncology field has delivered meaningful progress in the activation of T cells to fight cancer, yet current therapeutic approaches often fall short, with fewer than a third of patients experiencing a durable response.

Marengo scientists have applied a deep understanding of T cell biology and receptor signaling to uncover a new approach to T cell activation that promises to overcome the shortcomings of current immunotherapies. Marengo’s pioneering approach mimics natural mechanisms of non-clonal T cell receptor (TCR) activation, such as bacterial superantigen-induced TCR activation, and remodel the T cell compartment to unleash rapid, effective, and long-lasting anti-tumor responses.

Marengo’s therapeutic antibodies prime the activation of clonally diverse T cell populations within both CD8+ and CD4+ effector pools, which drives potent anti-tumor activity by “turbocharged” T cells and promotes long-term tumor immunity via “memory” T cells.

Vβ Antibodies Mimic Natural “Super” TCR Activators With Flexible/“Tunable” Properties of Antibody-fusion Molecules

Marengo’s Selective T Cell Activation Repertoire (STAR) platform elevates antibody design

Marengo’s proprietary Selective T Cell Activation Repertoire (STAR) platform channels the full power of immune cell activation.

STAR antibodies can be tailored to a broad range of therapeutic applications by switching out the specific Vβ TCR variants and cytokines being targeted. The technology can be customized to activate different effector immune cells (i.e. T cells, NK cells), and it can be plugged into various therapeutic constructs to treat a wide variety of refractory cancers.

FLEXIBLE DESIGN

Marengo’s customizable platform can select the desired T cell populations and modulate activation signals accordingly.

POTENT ANTI-TUMOR IMMUNE RESPONSE

Few T cell-activating antibodies have demonstrated functional memory and long-term protection in solid tumor models as a single agent in both IO sensitive and resistant models. Marengo’s approach expands a diverse army of cancer-fighting immune cells against a range of tumor antigens. Marengo’s technology has the potential for superior long-term efficacy in patients, and possibly remission.

FAVORABLE SAFETY PROFILE

In preclinical models, the Marengo fusion molecules selectively activate and expand cytotoxic T cells with limited cytokine release, which may translate into a better therapeutic index than current immune therapies.

Pipeline

A pipeline powered for progress

Marengo’s platform drives a transformative and comprehensive portfolio supported by the ongoing efforts of a dedicated, passionate team with deep experience in protein sciences, immunology and oncology.

Our first-in-class lead program, STAR0602, is an antibody fusion molecule that binds and activates a specific Vβ TCR variant T cell subset while also delivering additional signals to the same T cell (known as cis-targeting) to further reprogram the T cell, to enhance anti-tumor activity.

With profound single agent activity, the company’s products are being studied for use as monotherapies in initial development programs. Beyond monotherapy, Marengo intends to explore potential synergies with a range of IO and standard-of-care treatments.

Marengo is also advancing programs that engage other types of immune cells.

News & Investors

News

Investors

Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP’s strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.

Join Us

Our Values (4Cs)

Commitment

We have unparalleled commitment to patients and their loved ones.

Conviction

We are confident in our science and our team, and in their ability to successfully execute. Our team will adhere to the most rigorous scientific and global business standards in service of patients.

Courage

We operate with fearless spirit, unafraid to take on challenges in service of reaching our collective goal.

Creativity

We have the unique ability to apply deep expertise to new ways of thinking with curiosity and imagination. We leverage decades of experience and know-how to get the job done with care and precision.

Join Our Team

Marengo Therapeutics is seeking professionals who are motivated to make a positive difference in patients’ lives. If you’re interested in joining our collaborative team advancing cutting-edge disease-fighting therapies to the clinic and beyond, please explore our current openings or contact us at Recruiting@marengotx.com.

Marengo Therapeutics, Inc., provides equal employment opportunities to all qualified persons and prohibits discrimination in employment on the basis of race, ethnicity, national origin, ancestry, religion, creed, sex, sexual orientation, gender, gender identity or expression, age, veteran status, disability, genetics, or other protected status. In addition to federal law requirements, Marengo Therapeutics complies with applicable state and local laws governing nondiscrimination in employment. This policy applies to all terms and conditions of employment, including but not limited to those relating to recruiting, hiring, placement, promotion, termination, layoff, return from layoff, transfer, leaves of absence, compensation, and training.

Marengo Therapeutics offers a comprehensive benefits package including medical, dental, life insurance and disability; paid vacation, sick days and holidays; Flexible Spending Accounts and Healthy Lifestyle dollars; paid employee parking; and social hours and company events.